世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の人間用ワクチン市場 2018-2022年

Global Human Vaccine Market 2018-2022

IRTNTR21748

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
124

サマリー

この調査レポートは世界の人間用ワクチン市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Human Vaccine
Vaccines are biological preparations used to confer active acquired immunity against a host-causing disease. Vaccines have been impacting the global health scenario by reducing disease incidence, mortality rates, and life expectancy.
Technavio’s analysts forecast the Global Human Vaccine Market to grow at a CAGR of 7.73% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the human vaccine market. To calculate the market size, the report considers the revenue generated from the retail sales of human vaccines across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, human vaccines market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- GlaxoSmithKline
- Merck
- Pfizer
- Sanofi
Market driver
- Growing investments in vaccine segment
- For a full, detailed list, view our report


Market challenge
- Rising pricing pressure
- For a full, detailed list, view our report

Market trend
- Varied demand for vaccines in high-income and developing countries
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 08: MARKET SEGMENTATION BY ROA
- Segmentation by ROA
- Comparison by ROA
- Oral - Market size and forecast 2017-2022
- Intramuscular - Market size and forecast 2017-2022
- Intradermal - Market size and forecast 2017-2022
- Subcutaneous - Market size and forecast 2017-2022
- Intranasal - Market size and forecast 2017-2022
- Market opportunity by ROA
PART 09: MARKET SEGMENTATION BY VACCINE TYPE
- Market segmentation by vaccine type
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 14: MARKET TRENDS
- Varied demand for vaccines in high-income and developing countries
- Increase in strategic alliances and M&A
- Public-private partnership models and technology transfer to local players
- Innovative partnerships improving global vaccine access
- Emergence of new technologies for delivery of vaccines
- Differential pricing to accelerate uptake in low-income countries
PART 15: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 16: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- GlaxoSmithKline
- Merck
- Pfizer
- Sanofi
PART 17: APPENDIX
- List of abbreviations


-
-
Exhibit 01: Parent market
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline analysis
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global - Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: ROA - Market share 2017-2022 (%)
Exhibit 20: Comparison by ROA
Exhibit 21: Oral - Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Oral - Year-over-year growth 2018-2022 (%)
Exhibit 23: Intramuscular - Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Intramuscular - Year-over-year growth 2018-2022 (%)
Exhibit 25: Intradermal - Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Intradermal - Year-over-year growth 2018-2022 (%)
Exhibit 27: Subcutaneous - Market size and forecast 2017-2022 ($ bn)
Exhibit 28: Subcutaneous - Year-over-year growth 2018-2022 (%)
Exhibit 29: Intranasal - Market size and forecast 2017-2022 ($ bn)
Exhibit 30: Intranasal - Year-over-year growth 2018-2022 (%)
Exhibit 31: Market opportunity by ROA
Exhibit 32: Customer landscape
Exhibit 33: Global - Market share by geography 2017-2022 (%)
Exhibit 34: Regional comparison
Exhibit 35: Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 36: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in Americas
Exhibit 38: EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 39: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in EMEA
Exhibit 41: APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 42: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 43: Top 3 countries in APAC
Exhibit 44: Market opportunity
Exhibit 45: Major alliances and M&A in vaccine segment
Exhibit 46: Vaccines under development by small players
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: GlaxoSmithKline - Overview
Exhibit 53: GlaxoSmithKline - Business segments
Exhibit 54: GlaxoSmithKline - Organizational developments
Exhibit 55: GlaxoSmithKline - Geographic focus
Exhibit 56: GlaxoSmithKline - Segment focus
Exhibit 57: GlaxoSmithKline - Key offerings
Exhibit 58: Merck - Overview
Exhibit 59: Merck - Business segments
Exhibit 60: Merck - Organizational developments
Exhibit 61: Merck - Geographic focus
Exhibit 62: Merck - Segment focus
Exhibit 63: Merck - Key offering
Exhibit 64: Pfizer - Overview
Exhibit 65: Pfizer - Business segments
Exhibit 66: Pfizer - Organizational developments
Exhibit 67: Pfizer - Geographic focus
Exhibit 68: Pfizer - Segment focus
Exhibit 69: Key offering
Exhibit 70: Sanofi - Overview
Exhibit 71: Sanofi - Business segments
Exhibit 72: Sanofi - Organizational developments
Exhibit 73: Sanofi? Geographic focus
Exhibit 74: Sanofi - Segment focus
Exhibit 75: Sanofi - Key offering


-

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る